Table 4.
Age/Gender | Tier | Initial SBP, mm Hg | Initial NIHSS Score | Initial GCS Score | Time Interval Between Symptom Onset and Treatment | Cause of Neurologic Deterioration | Time Interval Between Initiation of Treatment and Deterioration | 1-mo and 3-mo mRS |
---|---|---|---|---|---|---|---|---|
55/F | 1 | 250 | 14 | 10 | 2.67 hrs | Hydrocephalus | 12 hrs | Lost to follow-up |
45/M | 2 | 192 | 8 | 15 | 2.75 hrs | Hematoma expansion | 5 mins | 1-mo mRS: 4 3-mo mRS: 3 |
59/F | 2 | 212 | 10 | 8 | 5.25 hrs | Hematoma expansion | 15 mins | 1-mo mRS: 5 3-mo mRS: 5 |
74/Ma | 3 | 219 | 5 | 15 | 5.23hrs | Hematoma expansion | 14.7 hrs | 1-mo mRS: 5 3-mo mRS: 6 |
43/M | 3 | 181 | 6 | 15 | 2.33 hrs | Hematoma expansion | Before infusion | 1-mo mRS: 4 3-mo mRS: 4 |
82/M | 3 | 183 | 34 | 13 | 3.92 hrs | Hematoma expansion | 18.75 hrs | 1-mo mRS: 6 |
46/M | 3 | 228 | 13 | 12 | 5.25 hrs | Hematoma expansion | 13.25 hrs | 1-mo mRS: 5 3-mo mRS: 4 |
M, male; F, female; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale.
Also had severe adverse events.